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Abstract In the present study a cancer risk assessment 
of occupational exposure to cyclophosphamide (CP), 
a genotoxic carcinogenic antineoplastic agent, was car­
ried out following two approaches based on (1) data  
from an animal study and (2) data on primary and 
secondary tum ors in CP-treated patients. D ata  on the 
urinary excretion of C P  in health care workers were 
used to estimate the uptake of CP, which ranged from 
3.6 to 18 p.g/day. Based on data from an animal study, 
cancer risks were calculated for a health care worker 
with a body weight of 70 kg and a working period of 40 
years, 200 days a year (linear extrapolation). The life­
time risks (70 years) of urinary bladder cancer in men 
and leukemias in men and women were found to be 
nearly the same and ranged from 95 to 600 per million. 
Based on the patient studies, cancer risks were cal­
culated by multiplication of the 10-year cumulative 
incidence per gram  of C P  in patients by the estimated 
mean to ta l uptake in health care workers over 10 years, 
200 days a year. The risk of leukemias in women over 
10 years ranged from 17 to 100 per million using the 
secondary tum or data  (linear extrapolation). C om para­
ble results were obtained for the risk of urinary bladder 
tumors and  leukemias in men and women when pri­
mary tum or data  were used. Thus, on an annual basis, 
cancer risks obtained from both  the animal and the 
patient study were nearly the same and ranged from 
about 1.4 to 10 per million. In The Netherlands it is 
proposed that, for workers, a cancer risk per com pound
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of one extra cancer case per million a year should be 
striven for (“target risk”) and that no risk higher than  
100 per million a year (“prohibitory risk”) should be 
tolerated. F rom  the animal and the patient study it 
appears that the target risk is exceeded but tha t the risk 
is still below the prohibitory risk.
Key words Antineoplastic agents * Biological 
monitoring • Occupational exposure • 
Cyclophosphamide * Cancer risk assessment
Introduction
Antineoplastic agents are widely used in the treatm ent 
of cancer and some non-neoplastic diseases [5 ,6 ]. De- 
pending on their mechanism of action, these drugs are 
subdivided into several categories, e.g., alkylating 
agents, antimetabolites, mitotic inhibitors, and  anti­
biotics. The alkylating agents express their cytotoxicity 
by interaction with the D NA of tum or cells. Because 
the desired cytotoxicity is not specific for cancer cells, 
normal cells may also be damaged, resulting in toxic 
side-effects. Carcinogenicity of a number of antineo­
plastic agents has been observed in animal studies and 
primary and secondary tumors have been found in 
patients treated with these drugs [4 ,10 ,11 ,13-17,21]. 
Cyclophosphamide (CP) is one of the most frequently 
used alkylating antineoplastic agents for different types 
of tumors [5,31]. According to the In ternational 
Agency for Research on Cancer, there is sufficient evid­
ence of carcinogenicity in humans and animals [13,14], 
D ue to its reactivity with D NA and mutagenicity in 
various short-term tests, CP is classified as a genotoxic 
carcinogen.
Because of the carcinogenic potency of CP and other 
antineoplastic agents, health care workers involved in 
the preparation and administration of these drugs may 
be at risk [30]. Therefore exposure to these com pounds 
should be avoided, and safety guidelines and protective
measures such as wearing masks, gloves, gowns, and 
special clothes and using laminar air-flow safety hoods 
have been introduced to protect workers when hand­
ling these drugs [1,29]. Nevertheless, in several studies 
it has been shown that uptake of CP does occur during 
occupational activities [24,25,27,28]. With a sensitive 
gas chromatographic-mass spectrometric method CP 
has been detected in the urine of health care workers 
handling antineoplastic drugs [26].
The risk of exposure to CP and other antineoplastic 
agents has been discussed in many studies [7,9,32]. 
However, a quantitative risk assessment could not be 
made because of the lack of the necessary exposure 
data. In this study we used data on the urinary excre­
tion of CP in health care workers to estimate the 
uptake of CP. Next, a cancer risk assessment was 
carried out following two approaches based on 
(1) data from an animal study and (2) data on primary 
and secondary tumors in CP-treated patients.
Although we realize that risk assessment of occupa­
tional exposure to carcinogens is a complex matter, we 
think that such data are necessary to set priorities in 
the protection of workers against genotoxic carcino­
gens. In this paper we present an initial approach to 
cancer risk estimation for health care workers exposed 
to CP. The pitfalls are discussed.
Materials and methods
Carcinogenicity studies in animals
Carcinogenicity of CP has been observed in several animal studies 
[13,14,21], For cancer risk assessment, studies are needed in which 
the animals are chronically exposed to at least two doses, preferably 
giving a clear dose-response relationship. Only the study of Schmahl 
and Habs appears to satisfy this requirement [20]. In this study male 
and female Sprague-Dawley rats were treated with CP in drinking 
water. The treatment started when the rats were 100 days old. Doses 
of 0,0.31,0.63,1.25 and 2.5 mg/kg body weight were administered, 
5 times a week, during their lifetime. Forty rats were used for each 
sex and dose. After a lifetime observation period, tumors of the 
urinary bladder and of the lymphoid and hematopoietic tissues 
(leukemias) were most frequently found and a dose-response rela­
tionship was obtained (Table 1). A statistically significant increase in 
leukemias was observed in males and females combined. Only in 
males was a statistically significant increase in tumors of the urinary 
bladder found.
Epidemiological studies in patients
Many cases o f cancer have been reported after therapeutic treatment 
with CP [4,10,11,13,14,16,17,21]. Among the various types of 
cancer, leukemias and tumors of the urinary bladder have been 
found most frequently not only as secondary tumors following 
cancer treatment but also as primary tumors after treatment for 
non-neoplastic diseases. In some of these studies the doses of CP 
were known and consequently the relative risks could be calculated 
[11,17]. The results of these studies showed a dose-dependent in­
crease in the relative risk of developing leukemias after treatment 
with CP for breast and ovarian cancer. For cancer risk assessment
Table 1 Urinary bladder tumors and leukemias from oral cyclo­
phosphamide treatment in male and female Sprague-Dawley ratsa
Dose 5 times of
week (mg/kg 
body weight)
Number of urinary 
bladder tumors
Number of 
leukemias
Males Females Males and Females
0 0/38 0/34 0/72
0.31 2/34 0/37 3/71
0.63 2/36 0/37 6/73b
1.25 5/3 5'= 0/33 6/68d
2.5 7/3 l e 1/27 4/5 8f
3 From Schmahl and Habs [20] 
b Fischer exact test: P — 0.015 
c Fischer exact test: P — 0.022 
d Fischer exact test: P — 0.011 
e Fischer exact test: P =  0.0024 
f Fischer exact test: P — 0.037
only data can be used from studies in which, in addition to the dose 
of CP administered, the tumor incidence is given. Both kinds of data 
were available, from two studies and these are briefly described 
below [4,10].
In five clinical trials the development of secondary leukemias was 
studied in 333 ovarian cancer patients treated with CP [10]. For the 
total group, a 10-year cumulative incidence of 5.4% was calculated. 
When the total group was subdivided into three dose groups, only in 
the highest dose group were leukemias observed, with a 10-year 
cumulative incidence of 11,1 %. For 1657 ovarian cancer patients not 
treated with CP a 10-year cumulative incidence of 0.1% was found.
The development of tumors was also studied in patients with 
rheumatoid arthritis treated with CP as an immunosuppressive 
agent [4]. A total of 119 patients (76 women) were treated with 
a mean CP dose of 52.9 g while 119 matched controls received no 
CP. Tumors were observed in 24.4% of the CP-treated patients 
during an observation period of 10.8 years. A tumor incidence of 
13,4% was observed in the matched controls during an observation 
period of 11.8 years. An increased incidence was observed for uri­
nary bladder tumors (6 vs 0), skin cancer (8 vs 0) and leukemias (5 vs 
1). The proportion of patients with tumors was significantly higher 
among men than women in the CP-treated group and in the control 
group. The increase in tumors between the control group and the 
CP-treated group was the same for men and women. Unfortunately, 
no information was available on sex-specific tumor types.
Estimation of the daily uptake
Despite the introduction of safety guidelines and protective 
measures, in several studies it has been shown that (health care) 
workers involved in the preparation and administration of antineo­
plastic agents like CP are exposed to this particular compound, since 
uptake was established by detection of CP in urine (Table 2) 
[8,12,24,25,27,28]. In order to avoid the use of unreliable data 
obtained from urinary CP excretion after a rather short period of 
only a few days, urine of eight hospital pharmacy workers was 
collected during two to four periods of 4 successive days. A total of 
476 urine samples were analyzed. CP was detected in one or more 
urine sample of each worker. The mean daily excretion was 0.18 jig 
(range: 0.01-0.53 jig). These urinary excretion levels are the basis for 
the estimation of the exposure. In urine samples with undetectable 
amounts of CP the amounts excreted were set at zero.
It is supposed that during occupational activities antineoplastic 
agents like CP are absorbed by inhalation and via dermal penetra­
tion [2,12,18,27]. Such exposure conditions were imitated in rats by
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Table 2 Range of cyclophosphamide in urine of (health care) workers exposed to antineoplastic agents
Group No. of 
workers
Period of urine 
sampling (days)
Mean amount“ (range) of Reference 
CP in urine (ng/day)
Health care workers 20 4 0.39 (0-2.5) Evelo et al. [8]
Nurses 2 57b 0.47 (0.43-0.5 l )c Hirst et al. [12]
Pharmacy technicians 2 2 0 Sessink et a l  [23]
Pharmacy technicians 25 1-2 0.05 (0-0.5) Sessink et al. [24]
Animal caretakers 4 2-5 0.05 (0-0.2) Sessink et al. [25]
Pharmacy technicians1 9 1-2 1.36 (0-10.05) Sessink et al. [27]
Pharmacy technicians6 9 5 0.16 (0-0.51 Unpublished
Nurses 8 1 0.79 (0-2.9) Sessink et al. [28]
Pharmacy technicians 1
Cleaning women 2
Nurses 7 2-4 0.80 (0-4.2) Unpublished
Pharmacy technicians 8 8-16 0.18 (0.01-0.53) This study
a Amounts below the detection limits were set at zero 
b In both nurses urine sampling was performed over a total of 57 days 
c Mean and range were calculated by assuming a mean sampling period of 282 days 
d The same persons
intratracheal instillation and dermal application of a single CP dose 
of I mg/kg body weight [22]. For both treatments a total of about 
5% of the applied dose was excreted unchanged in urine, all within 
24 h. Application of 1 mg CP on the skin of volunteers revealed 
a urinary excretion of about 1% [12]. The mean uptake of CP was 
calculated by multiplication of the mean daily urinary CP excretion 
of 0.18 |ig by 20 (5% excretion after dermal and intratracheal treat­
ment of rats) or 100 (1% excretion after dermal application in 
volunteers). Hence, it was estimated that the mean daily uptake of 
CP will range from 3.6 to 18 jig.
Cancer risk assessment based on the animal study
Cancer risks were estimated using linear extrapolation and assum­
ing that the time dependence of tumor development is more likely 
related to the cumulative dose of CP than to life span and the rate of 
aging [19]. The model is based on intersection of a straight line 
between zero dose and the lowest dose in the animal experiment at 
which a significant increase in tumors is observed (Table 1). From  
the results of the study of Schmahl and Habs, the median survival 
periods of the rats at the different doses were obtained [20]. To 
calculate the exposure periods, the survival periods were reduced by 
100 days (at the start of the experiment the rats were 100 days old) 
and multiplied by 5/7 (the rats were administered CP 5 times 
a week). The total cumulative CP doses were calculated by multipli­
cation of the doses by the exposure periods. The cancer risks per mg 
CP were calculated by dividing the tumor incidences by the total 
cumulative CP doses. Finally, lifetime cancer risks for health care 
workers were calculated by multiplication of the cancer risks per mg 
CP in rats by the total cumulative CP uptake of the health care 
workers over a working (exposure) period of 40 years (range: 
28.8-144 mg) and the results were divided by body weight. An 
overview of the calculated data is given in Table 3.
Cancer risk assessment based on the epidemiological studies
1 ,
1
From the study of Greene et al., the 10-year cumulative cancer risk 
per gram was calculated by using the median dose of 19.5 g among 
the total group and the corresponding 10-year cumulative cancer 
incidence of 5.4% [10]. A linear dose-response curve was construc­
ted, using the 10-year cumulative cancer risk of 0.1% which was
observed in the control group of patients without C P treatment. 
Finally, a 10-year cumulative cancer incidence of 0.27% per gram  
was calculated. A 10-year cumulative cancer incidence of 0.24% per 
gram was calculated by using the data of the highest dose group of  
46,35 g and the corresponding 10-year cumulative cancer incidence 
of 11.1%.
The same procedure was followed for the results of the study by 
Baker et al, [4]. The 10-year cumulative cancer risk difference 
between CP-treated patients and control patients was calculated by 
linear extrapolation from the measured 10.8-year observation period 
to a 10-year period. The mean dose was 52.9 g, resulting in a 10-year 
cumulative cancer incidence of 0.21% per gram.
Results
t.
Cancer risk assessment based on the animal study
Cancer risks were calculated for a health care w orker of 
70 kg body weight and a working (exposure) period of 
40 years, 200 days a year. Within the range of the 
estimated m ean daily CP uptake of 3.6-18 |rg (total 
cumulative C P uptake over 40 years: 28.8-144 mg), the 
calculated lifetime risks of urinary bladder cancer in 
men and leukemias in men and women were nearly the 
same and ranged from 120 to 600 per million and from 
95 to 475 per million, respectively (Table 3).
Cancer risk assessment based on
4
epidemiological studies
Cancer risks were calculated by multiplication o f the 
10-year cumulative incidence per gram of C P  in 
patients by the estimated mean total C P uptake in, 
health care workers over 10 years, 200 days a year, 
based on the estimated mean daily uptake of 3.6-18 (ig 
(total cumulative CP uptake over 10 years: 7.2-36 mg). 
N o  differences were found in the study on secondary
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Table 3 Cancer risk 
calculations for health care 
workers obtained by linear 
extrapolation using incidence o f  
tumors of the urinary bladder 
in male rats and of leukemias in 
male and female rats3
Parameter Urinary bladder tumors Leukemias
Rat
Lowest dose with significant increase
«
in tum orsb
(mg C P/kg body weight per day)
1.25 0.63
Tum or incidence*5 (%) 14.3 8.2
M edian survival period (days) 646 889
Exposure period (days) (646 — 100) x 5/7 =  390 (889 -  100) x 5/7 =  564
Total cumulated dose (mg C P/kg
body weight)
Cancer risk per mg C P (kg
1.25x 390 =  487.5 0.63 x 564 =  355
body weight/mg CP) 0.143/487.5 =  293 x lO "6 0.082/355 =  233 x 10’ 6
Health care worker
Lifetime cancer riskc (per million) 1/70 x 293 x (28.8-144)
-  120-600 1/70 x 233 x  (28.8-144) 
=  95-475
a From  Schmahl and Habs [20] 
b From  Table 1
c 70 kg body weight; total cumulative CP uptake over 40 years: 28 .8-144 mg
Table 4 Cancer risks for health 
care workers obtained from 
tumor incidence data of 
patients
Patients3 Exposed workersb Reference
C P dose (g) Cancer risk (per million) Cancer risk (per million)
Leukemias in women
19.5C 54000  20-100  
46.35d 111000 17-86 
0e 1000
Urinary bladder tumors and leukemias in men and women
52.9F 112000 15-76
Greene et al. [10] 
Baker et al. [4]
a 10-year observation period
b 10~year exposure period (total cumulative CP uptake over 10 years: 7 .2-36 mg) 
c Median dose  
d Highest dose group 
c Control group without CP treatment 
f Mean dose
tum ors by G reene  et al. between the results based on 
calculations with the m edian  dose of the to tal g rou p  of 
19.5 g and  the  highest dose g roup  of 46.35 g (Table 4) 
[10]. In  b o th  cases cancer risk ranged  from  ab ou t 17 to 
100 per million. A marginally low er cancer risk of 15 to 
76 per m illion was obtained when prim ary tum or d a ta  
from the study  of Baker et a l  were used (Table 4) [4].
Discussion
In  the p resen t study a cancer risk assessment of occupa­
tional exposure  to C P  w as carried out following two 
approaches based  on (1) d a ta  from an anim al study 
and (2) d a ta  on prim ary  and  secondary tum ors in
C P-treated  patients. D u r in g  this opera tion  several a s ­
sumptions were made, and  these are discussed below .
T um or type
The same tum or types, nam ely  u rin a ry  bladder tu m o r s  
and leukemias, were found  in the  anim als an d  in t h e  
patients. It is rem arkab le  th a t  u rina ry  b ladder tu m o r s  
only appeared in male rats  while leukemias were o b ­
served equally in m ale an d  female rats. U n fo r tu n a te ly ,  
no inform ation is available from  the patien t study o f  
Baker et al. with respect to  the sex-specific induction  o f  
urinary bladder tum ors [4]. C onsequently  it is a s s u m e d  
that no sex differences were present. Because the s tu d y  
of Greene et al. only included w om en, it rem ains i m -
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possible to establish whether leukemias were induced 
in a sex-specific manner [10]. For extrapolation of the 
results of the animal study and patient studies this 
means that; (1) the animal study may only be used for 
risk assessment of urinary bladder tumors in men and 
of leukemias in men and women, (2) extrapolation from 
the patient study of Greene et al. is restricted to risk 
assessment of leukemias in women, and (3) it is assumed 
that the patient study of Baker et al. is suitable for the 
risk assessment of urinary bladder tumors and 
leukemias in men and women [4,10].
Estimation of the daily uptake
For the estimation of the mean daily CP uptake, the 
excretion of unmetabolized CP in urine was investi­
gated. In order to obtain accurate information about 
the daily CP excretion in urine, urine samples were 
collected from several persons over two to four periods 
of 4 successive days. In this way incidentally extremely 
high levels were averaged and overestimation was mini­
mized. Nevertheless, a large interindividual difference 
in CP excretion was obtained, undoubtedly due to 
interindividual differences in uptake and/or biotrans­
formation of CP. In order to compare the results of 
the different studies in a proper way, undetectable 
amounts of CP were set at zero. This results in an 
underestimation of the cancer risk. For the estimation 
of the uptake, we used results of studies in which 
relatively low amounts of CP were administered to rats 
and volunteers. Data of patients were not used because 
the amounts of CP administered were much higher 
than would be expected after occupational exposure.
The results of the animal study showed that a total of 
about 5% of a single CP dose of 1 mg/kg body weight 
was excreted in urine, all within 24 h, irrespective of the 
route of exposure (intratracheal, dermal, oral, or intra­
venous) [22]. Lowering of the dermally applied dose to 
0.1 and 0.01 mg/kg body weight resulted in excretion 
percentages of 8.3% + 2.1% and 5.1% ± 2.9%, 
respectively (mean ± SD, n =  5); these figures are not 
significantly different from one another (unpublished 
results). Therefore the excretion of unmetabolized CP is 
estimated to be about 5% of the administered dose. It is
_
unclear why the percentage recovery of CP in urine in 
the volunteer study was only about 1% [12]. This may, 
of course, have been due to interspecies differences, but 
on the other hand it may also have been the result of 
incomplete absorption by the human skin. This latter 
possibility, which seems quite reasonable, would lead 
to an overestimation of both mean daily uptake and 
cancer risk if 1 % excretion is taken as a starting point. 
Nevertheless, this is the only study in which volunteers 
have been treated with a relatively low CP dose. It 
should also be pointed out that the influence of chronic 
low-dose exposures by different exposure routes on the 
excretion percentage remains unknown.
Extrapolation
The data from the animal study showed a linear dose- 
response curve between daily CP dose and cancer risk. 
Consequently, linear extrapolation was used for cancer 
risk assessment. It should be noted that cancer risk is 
not primarily caused by the amount of CP absorbed 
but depends on the amount of phosphoramide mustard 
formed after biotransformation [31]. The formation of 
phosphoramide mustard results in the alkylation of 
target DNA and cancer risk is expected to correlate 
better with the amount of phosphoramide mustard able 
to bind to target tissue. On the basis of the linear 
dose-response relationship in the animal study between 
CP dose and cancer risk we assume that the amount of 
phosphoramide mustard increases linearly with the CP 
dose. Since biotransformation of CP in man and rat 
are similar, it is also reasonable to assume that in 
patients the amount of phosphoramide mustard will 
increase linearly with the dose [13,31]. This explains 
our choice of the linear extrapolation when using the 
patient data.
Cancer risk
The results of the animal study showed a lifetime risk 
(70 years) of urinary bladder tumors in men and of 
leukemias in men and women of 95-600 per million 
after a period of CP exposure of 40 years, 200 days 
a year. Comparable cancer risks of 1.5-10 per million 
a year were estimated from the patient studies. It 
should be noted that in the animal study the number of 
lifetime cases was indicated while the cancer risk in 
patients was estimated on an observation period of 10 
years. Since it is unclear how the dose-response curve 
will be after the 10-year observation period, it is not 
possible to show what the consequences will be for 
lifetime cancer risks. Therefore the calculated risks 
most probably are underestimates. It should also be 
noted that in the patient study of Greene et al. a pos­
sible predisposition of the patients under consideration 
may have resulted in higher cancer incidences upon 
treatment with genotoxic carcinogens [10]. It should 
be emphasized that in the study of Baker et al. the total 
cancer risk was assessed [4]. Not only urinary bladder 
tumors and leukemias were considered but also other 
types of cancer, especially skin cancer. This may partly 
explain the lower cancer risk calculated from the ani­
mal study as only urinary bladder tumors and 
leukemias could be taken into account here. Risks 
based on animal data should be calculated from the 
number of tumor-bearing animals, i.e., the sum of the 
number of animals having tumors at sites that show 
a statistically increased incidence as compared to con­
trols. Unfortunately, the data of Schmahl and Habs do 
not allow such an approach, which might have resulted 
in higher estimated cancer risks [20].
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Cancer risk and legislation
In the United States, Sweden, Germany, and the Euro­
pean Union, threshold limit values or comparable max­
imum exposure levels have been introduced for some 
(genotoxic) carcinogens in order to protect workers [3]. 
In The Netherlands it is proposed that, for workers, 
a cancer risk for each compound of 1 extra cancer case 
per million a year should be striven for (“target risk”) 
and that no risk higher than 100 per million a year 
(“prohibitory risk”) should be accepted [3], From the 
animal and the patient study it appeared that the target 
risk is exceeded but that the risk is still below the 
prohibitory risk. Nevertheless, it should be noted that 
in some studies groups of workers have excreted higher 
amounts of CP than the mean daily CP excretion of 
0.18 jig in the present study, consequently resulting in 
higher cancer risks (Table 2).
It should be emphasized that this risk assessment 
was based on exposure to one single antineoplastic 
agent while it is known that more antineoplastic agents 
are used for which no exposure data are available. 
However, it is reasonable to assume that exposure to all 
antineoplastic agents will occur in a similar manner 
because the drugs are mostly handled in a comparable 
way. In fact, this means that the cancer risk might be 
higher than assessed in the present study, supposing 
that no antagonistic interaction takes place. However, 
this is not of influence in the possible surpassing of 
target and prohibitory risk levels because these are 
based on single compounds.
In conclusion: The calculated cancer risk due to 
occupational exposure to CP was based on available 
dose-response data and on the indirect assessment of 
CP exposure by measuring CP excretion in urine. Al­
though the presented cancer risk assessment due to 
exposure to CP has its limitations, the cancer risks 
calculated from CP exposure of health care workers 
indicate that these workers still have higher risks for 
cancer due to the handling of CP and/or other anti­
neoplastic agents in spite of the protective measures 
that have been taken.
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